Michael Torgov

University of Santa Monica — United States

Medicine · Health Sciences

13h-index2.7kcitations54works2.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(31), CAR-T cell therapy research(25), Radiopharmaceutical Chemistry and Applications(15), Viral Infectious Diseases and Gene Expression in Insects(7), Boron Compounds in Chemistry(7)

Publications53 total

First estimation of the clinical utility of boronotyrosine as a boron delivery compound for boron neutron capture therapy in head and neck cancer
Applied Radiation and Isotopes·2026
BORONTYROSINE BIODISTRIBUTION AND MICRODISTRIBUTION STUDIES FOR BORON NEUTRON CAPTURE THERAPY: PRELIMINARY STUDIES IN AN EXPERIMENTAL ORAL CANCER MODEL
International Journal of Particle Therapy·2025Open Access
AB012. Tissue uptake of novel boron neutron capture therapy compounds in a mouse model, with pharmacokinetic and dosimetric extrapolation to human treatment
Therapeutic Radiology and Oncology·2025Open Access
Exploratory Rat Toxicology and Efficacy of the Boron Neutron Capture Therapy Drug Boronotyrosine in a Mouse Model of Head and Neck Cancer
International Journal of Radiation Oncology*Biology*Physics·2025· 1 cited
First Estimation of the Clinical Utility of Boronotyrosine as a Boron Delivery Compound for Boron Neutron Capture Therapy in Head and Neck Cancer
SSRN Electronic Journal·2025· 1 citedOpen Access
First estimation of the clinical utility of boronotyrosine as a boron delivery compound for boron neutron capture therapy in head and neck cancer
SSRN Electronic Journal·2025Open Access
First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy
European Journal of Nuclear Medicine and Molecular Imaging·2024· 17 citedOpen Access
1485: Development of GLUT-1 targeted boron carriers for Boron Neutron Capture Therapy (BNCT)
Radiotherapy and Oncology·2024
Superiority of BNCT Treatment Planning Metrics Achieved Using Novel vs. Reference (BPA-F) Pharmaceuticals in Head and Neck Locations
International Journal of Radiation Oncology*Biology*Physics·2023Open Access
Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field
Journal of Medicinal Chemistry·2023· 25 cited
Figure S4 from The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
2023Open Access
Figure S1 from The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
2023Open Access
Figure S5 from The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
2023Open Access
Figure S6 from The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
2023Open Access
Figure S5 from The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
2023Open Access
Figure S6 from The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
2023Open Access
Data from The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
2023Open Access
Figure S4 from The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
2023Open Access
Figure S3 from The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
2023Open Access
Figure S2 from The PET-Tracer <sup>89</sup>Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Jean Gudas(24), Tove Olafsen(22), Daulet Satpayev(19), Alessandro Mascioni(18), Green Zhang(18), Ian A. Wilson(18), Christoph M. Griessinger(17), Jason M. Romero(17), Filippo Marchioni(17), Valeria Nicolini(17), Johannes Sam(17), Christina Claus(17), Claudia Ferrara(17), Marina Bacac(17), Pablo Umaña(17), Christian Klein(17), Jean Tessier(17), Ziyue Karen Jiang(16), Charles Zamilpa(16), Fang Jia(16)